We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




The Plant Derivative Celastrol Prompts Cancer Cells to Self-Destruct

By LabMedica International staff writers
Posted on 16 Feb 2010
Celastrol, an anti-inflammatory plant derivative long used in Chinese medicine, has been found to have potential as an anticancer drug due to its ability to inhibit the procancer protein p23.

Investigators at the Medical College of Georgia (Augusta, USA) were studying the effect of celastrol on the heat shock protein HSP90, a key modulator of the inflammatory response and linked to both autoimmune diseases and cancer.

They reported in the February 5, 2010, issue of the Journal of Biological Chemistry that celastrol inhibited the Hsp90 chaperoning machinery by inactivating the cochaperone p23, resulting in selective destabilization of steroid receptors. More...
In vitro and in vivo results demonstrated that celastrol disrupted p23 function by altering its three-dimensional structure, leading to rapid formation of amyloid-like fibrils.

"The celastrol induces the protein to form fibrils and clusters it together, which inactivates it,” explained senior author Dr. Ahmed Chadli, professor of biochemistry at the Medical College of Georgia. "When they are clustered, they are not available for other functions that help cancer grow."

"Cancer cells need HSP90 more than normal cells because cancer cells have thousands of mutations,” said Dr. Chadli. "They need chaperones all the time to keep their mutated proteins active. By taking heat shock proteins away from cells, the stabilization is taken away and cell death occurs.”

Related Links:
Medical College of Georgia



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.